Physiomics plc

The Magdalen Centre
The Oxford Science Park
Robert Robinson Avenue
Oxford
OX4 4GA
UK

Tel 01865 784980
Fax 08701 671931

11 June 2013

Physiomics plc

("Physiomics") or ("the Company")

Physiomics to present on the new R&D development at the Population Approach Group Europe meeting 2013 ("PAGE")

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the PAGE Meeting 2013, taking place at the Glasgow Royal Concert Hall, Glasgow, on 11-14 June 2013. Dr Eric Fernandez, Dr Frances Brightman, and Dr Christophe Chassagnole will present on an updated version of drugCARD, on our newly release cardiac toxicity predictive platform and on our emerging Virtual Tumour clinical platform.

DrugCARD, a new database of anti-cancer drugs and therapeutic treatment information, is the result of collaboration between Physiomics and Pharmacometrics. The first poster will show how researchers and clinicians can rapidly access and search pre-clinical and clinical drug regimen data. The database is in its final stages of testing before its release.

In the second poster we will present how our new cardiac toxicity model predicts the risk of a fatal heart arrhythmia known as Torsade de Pointes, using low cost and relatively easy to obtain lab-based data. Torsade de Pointes has been responsible for numerous market withdrawals in the last two decades.

The results presented in the third poster show how we have extended the capabilities of our pre-clinical Virtual Tumour™ model to the clinic. In this literature based case study we have been able to qualitatively predict that certain combination schedules already explored in the clinic can lead to very different outcomes depending on the sequence used.

Two of the abstracts ("drugCARD: a database of anti-cancer treatment regimens and drug combinations" and " Virtual Tumour Clinical: Literature example") will be presented in the Oncology session, whereas the third one ("Predicting Torsades de Pointes risk from data generated via high-throughput screening") will be presented in the New Modelling approaches session.

More information about the conference may be found at:
http://www.page-meeting.org/default.asp?id=37&keuze=meeting

Dr Mark Chadwick, CEO of Physiomics, commented:
"We are delighted to present three approved posters at this year's PAGE meeting, demonstrating the progress we have made with our new products."

Enquiries:

Physiomics plc
Dr Mark Chadwick, CEO
+44 (0)1865 784 980

WH Ireland Limited (broker/nomad)
Katy Mitchell
+44 (0) 161 832 2174

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million[1].

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

[1]Tufts Centre Impact Report 2002